Old Web
English
Sign In
Acemap
>
Paper
>
P76.57 Resistance Mechanisms to Osimertinib Upon it’s Line of Therapy in Patients with EGFR+ NSCLC and Beyond
P76.57 Resistance Mechanisms to Osimertinib Upon it’s Line of Therapy in Patients with EGFR+ NSCLC and Beyond
2021
Vered Fuchs
L. Roisman
Waleed Kian
Roni Gillis
N. Peled
Keywords:
Medicine
Internal medicine
Oncology
line of therapy
in patient
Osimertinib
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]